Understanding how arginine methylation affects cancer treatment
Regulatory Mechanisms of Arginine Methylation
This study is looking at how certain proteins in our bodies, called PRMTs, might affect cancer growth and treatment, with the hope of finding better ways to help patients like you respond to therapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-11097375 on NIH RePORTER |
What this research studies
This research investigates the role of arginine methylation, a common modification of proteins, in cancer biology. It focuses on how specific enzymes, known as protein arginine methyltransferases (PRMTs), regulate cellular processes that are crucial for cancer progression and treatment response. By exploring the mechanisms of these enzymes and their interactions with other proteins, the research aims to uncover new insights that could lead to improved cancer therapies. Patients may benefit from findings that enhance the effectiveness of existing treatments or lead to the development of novel therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients whose tumors exhibit deregulation of arginine methylation processes.
Not a fit: Patients with cancers that do not involve arginine methylation or those who are not undergoing treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by targeting the mechanisms of arginine methylation.
How similar studies have performed: Previous research has shown promising results in targeting posttranslational modifications like arginine methylation in cancer therapy, suggesting potential for success in this area.
Where this research is happening
Charleston, United States
- Medical University of South Carolina — Charleston, United States (Active)
Researchers
- Principal investigator: Gan, Wenjian — Medical University of South Carolina
- Study coordinator: Gan, Wenjian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.